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cyclophosphamide cannot be recommended, we suggest
Detection of fragments ofthat there is available evidence to support the use of
dipyridamole and low-dose warfarin. This regimen has
b2-microglobulin inbeen shown to be safe and its use as long-term therapy
in patients with IgA nephropathy with poor prognostic
amyloid fibrilsindices can slow the rate of decline in renal function and
progression to ESRD.
To the Editor: A major controversy regarding dialysis
related amyloidosis (DRA) is about the presence and
K.T. Woo, G.S.L. Lee, and Abeed A. Pall the role of truncated forms of b2-microglobulin (b2M)Department of Renal Medicine, Singapore General Hospital,
in the amyloid fibrils. Whereas Linke et al have reportedSingapore
the presence of proteolyzed forms of b2M in the amyloid
Correspondence to Dr. K.T. Woo, Department of Renal Medicine, deposits in over 12 cases [1], other groups have not con-
Singapore General Hospital, Outram Road, Singapore 169608. firmed this finding [2]. A similar analysis conduced in
our laboratory with b2-fibrils obtained from six patients
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Reply from the authors can be expected. We think that the use of a protein
sequenator like the HP G1000, in use in our laboratory,To the Editor: Drs. Woo, Lee, and Pall correctly as-
where it is possible to analyze samples in GdnHCl with-sumed that the study “Three-year randomized controlled
out further handling, could avoid the loss of even pmolestrial of dipyridamole and low-dose warfarin in patients
of misfolded b2M fragments.with IgA nephropathy and renal impairment” (Nephrol-
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we are concerned by the small number of patients in-
ACKNOWLEDGMENTSvolved in this study. Future trials hopefully will clarify
This study was supported by MURST and Progetto di Ateneo Uni-the appropriate evidence-based recommendation for di-
versita` di Pavia.pyridamole and warfarin use in IgAN treatment.
Maryse Courteau and Linda Nolin Correspondence to Vittorio Bellotti, M.D., Dipartimento di Biochim-
Nephrology Division, Centre Hospitalier de l’universite´ de ica, Universita` di Pavia, Via Taramelli 3b, 27100 Pavia, Italy.
E-mail: vbellot@unipv.itMontre´al, Montre´al, Quebec, Canada
